tirzepatide surmount-1 weight loss percent 72 weeks results reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism Effect of once-weekly tirzepatide on

Why Does Semaglutide Cause Burping

Neuroprotective effects of angiotensin receptor blockers

Accidental Overdose: Be especially careful not to confuse syringes (using a U-100 syringe with U-500 insulin, for example, can cause a 5-fold dosing error!)

The data from the two trials were pooled together to calculate a reduced risk for major adverse CV events with the addition of semaglutide to standard of care (HR = 0.76

Knowing which foods to avoid is important

In head-to-head comparison data from the SURMOUNT trial program, tirzepatide at the 15 mg dose produced mean weight reductions of 22.5% over 72 weeks, blowing past what semaglutide achieves on its own [1]